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ARA = American Rheumatism Association; EULAR = European League Against Rheumatism; HLA = human leukocyte antigen; IL = interleukin;
ILAR = International League of Associations for Rheumatology; JIA = juvenile idiopathic arthritis; JRA = juvenile rheumatoid arthritis; λs = sibling
recurrence risk; MIF = macrophage migration inhibitory factor; SNP = single nucleotide polymorphism; TCR = T-cell receptor; TNF = tumour necro-
sis factor.
Arthritis Research    Vol 4 No 5 Thomson and Donn
Introduction
It is necessary to define the genetic component of any
disease in order to enhance the understanding of its
pathogenesis, imply its aetiology and refine its treatment.
The most rapid progress towards such aims is best
achieved when there is homology of the expressed form
(phenotype). Unfortunately, progress in defining the
genetic components of childhood arthritis has long proven
difficult, for two reasons. Firstly, childhood inflammatory
arthritis is not a single disease but a group of clinical syn-
dromes. Secondly, since its first description in the late
1890s, classification of the chronic arthritides of child-
hood has been problematic. Ansell and Bywaters [1] first
proposed that classification should be based on the char-
acteristics of disease at onset and this basic premise still
remains. This premise has led to the development of two
related but importantly different classifications, juvenile
chronic arthritis as defined by EULAR and juvenile
rheumatoid arthritis (JRA) as defined by the American
Rheumatism Association (ARA). The major differences are
the disease duration (minimum of 3 months for EULAR,
6 weeks for ARA) and the fact that the EULAR criteria are
inclusive of other forms of juvenile arthritis, such as juve-
nile ankylosing spondylitis, inflammatory bowel disease
and juvenile psoriatic arthritis, whereas the ARA criteria
are exclusive.
These problems have hindered genetic studies. In addi-
tion, the relatively small patient numbers in some of the
disease subgroups significantly reduces the power of any
study to detect a ‘real’ effect. Also, the determination of
true genetic effects relies heavily on the replication of
results in identical patient populations but transatlantic dif-
ferences in classification have made this virtually impossi-
ble. In an attempt to solve these issues, a new
classification system, the ILAR classification, has been
developed. It aims both to unify the previous classification
systems so as to minimise international differences in
disease definition and to identify clinically homogenous
disease subgroups within the umbrella term JIA and thus
facilitate research [2].
Juvenile idiopathic arthritis (JIA) indicates a disease of
childhood (i.e. less than 16 years of age) of no known aeti-
ology, characterised by arthritis persistent for at least
6 weeks. Classification is made at 6 months after diagno-
sis into one of eight disease categories, each of which has
its own specific characteristics, exclusions and descrip-
Studies have established the magnitude of the genetic basis of juvenile idiopathic arthritis (JIA). JIA is a
complex genetic condition and the genes that influence susceptibility are actively being sought. A
candidate gene approach is being used by several groups. MHC-, cytokine- and T-cell-related genes
have all been positively associated with JIA. Here we review some of the latest genetic data, and
discuss ways in which JIA genetic research might proceed.
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tors. Validation of the ILAR classification is still in
progress. Despite these challenges, progress within the
area of JIA genetics is being achieved.
Evidence for a genetic component to juvenile
idiopathic arthritis
Evidence for a genetic component to a disease can come
from a variety of sources such as twin studies, family
studies or association studies. As JIA is a relatively rare
disease, accounts of twin and family studies are quite
uncommon and often based on small numbers. Recent
data from the USA and Finland, however, suggest that the
genetic contribution to JIA may be quite considerable.
Within the USA, the National Institute of Arthritis and Mus-
culoskeletal and Skin Diseases has sponsored a research
registry for JRA-affected sibling pairs. Initial analysis of 71
affected sibling pairs showed that 63% were concordant
for gender and 76% for onset type [3]. This study also
provided the first estimate of the sibling recurrence risk
(λs) for JRA; this was 15 (a value similar to those for
insulin dependent diabetes mellitus and multiple sclero-
sis), although this is likely to vary between subgroups.
Such a high λs is indicative of a factor shared between
siblings – genetic or environmental. In a more recent
analysis of 118 affected sibling pairs, 14 pairs of twins
were identified in which both twins have arthritis. One pair
comprises a girl with polyarthritis and a boy with persistent
oligoarthritis. The other 13 pairs (11 monozygotic, 2 dizy-
gotic and 2 of unknown zygosity) were concordant for
gender (nine female, four male), disease onset (10 paucia-
rticular, 3 polyarticular) and disease course (eight pauciar-
ticular, five polyarticular) [4].
Within Finland, 41 JIA multicase families with 88 affected
siblings have been collected over a period of 15 years.
This study estimates the λs of JIA to be nearer 20 [5].
Within this set of families there were eight sets of monozy-
gotic twins, two of which were concordant for JIA. Both
sets of twins were concordant for disease course but
were unexpectedly different for disease onset [6]. A con-
cordance rate of 25% for a disease with a population
prevalence of 1 per 1000 implies a relative risk of 250 for
a monozygotic twin. All these data (American and Finnish)
taken together provide convincing evidence that there is a
substantial genetic component to JIA.
Juvenile idiopathic arthritis and the MHC
Much of the genetic work undertaken in the past three
decades centred round HLA genes. These earlier studies
of HLA and JIA included children classified according to
either the EULAR or the ACR criteria. Numerous studies
of associations of JIA with both HLA class I and class II
genes have been described, with the class I associations
being consistently more limited than those for class II.
These studies have been reviewed elsewhere [7]. More
recently, linkage to HLA has now been confirmed in two
populations [8,9].
Studies of non-HLA genes within the MHC have been
limited. Positive associations have recently been
described, however, between LMP7 and early-onset
pauciarticular JRA, and between the gene encoding
Tapasin with systemic-onset JRA [10,11].
Candidate gene selection in juvenile
idiopathic arthritis
Several aspects can be considered when selecting genes
for investigation in JIA. The nature of the histopathology of
the inflamed synovium is one starting point. Evidence for
the underlying driving force for the chronic synovitis of JIA
being antigen-driven and T-cell mediated has been well
documented in a recent review by Grom & Hirsch [12].
Arguably, another important starting point for genetic
investigation is raised levels of protein expression in
affected children. Keys to the pathogenesis of JIA may be
provided by changes in the secretion patterns of particular
proteins, as measured by bioassays; alternatively, these
proteins could simply be present at altered levels as a
result of ‘bystander effects’, having little to do with the
pathogenic mechanism. Studying the genetic variation of
such candidates should help to elucidate this ‘cause’ or
‘effect’ conundrum. To be effective the functional polymor-
phism(s) need to be studied. These are generally not pre-
determined. Hence to fully investigate a gene it may be
necessary to study all the single nucleotide polymor-
phisms (SNPs) within it.
Cytokine gene polymorphisms and juvenile
idiopathic arthritis
Tumour necrosis factor
The involvement of tumour necrosis factor (TNF) protein and
its receptors in the pathology of JIA has been suggested by
multiple studies. The genetic evidence in support of these
observations, however, is much scarcer. Date et al. [13]
showed the frequencies of polymorphisms at the –1031,
–863 and –857 positions of the TNF promoter to be signifi-
cantly higher in a group of Japanese systemic-onset JIA
patients compared with those observed in controls. Also,
particular alleles of a microsatellite marker in the TNF-α
gene were found to be strongly associated with early-onset
pauciarticular juvenile arthritis in German patients [14].
Ozen et al. [15] studied the TNF –308 and –238 polymor-
phisms in Czech and Turkish JIA patients, but found no
association with either polymorphism. In contrast, Zeggini et
al. [16] have reported positive association with TNF poly-
morphisms in a large panel of UK Caucasian oligoarticular
JIA patients. The TNF locus is highly polymorphic and
several of the SNPs that have so far been described have
potential functional significance. Clearly, more studies of the
polymorphisms of TNF in JIA patients are required.304
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Interleukin 6
Many of the clinical features of systemic-onset JIA are
typical of excessive IL-6 production, for example fever,
hypergammaglobulinaemia, thrombocytosis, anaemia and
stunted growth. A functional polymorphism that deter-
mines the transcriptional response of the IL-6 gene to IL-1
and lipopolysaccharide was identified recently (as –174 in
the regulatory region of the IL-6 gene). There was a signifi-
cant lack of the protective genotype (CC: low producer of
IL-6 on stimulation by IL-1/lipopolysaccharide) in children
that develop systemic JIA at age 5 and under [17]. In a
recent study by Pignatti et al. [18], however, this was not
replicated. Similarly, the –174 polymorphism was not
shown to be associated with UK systemic-onset JIA (or
any other JIA subgroup) in a study by Donn et al. [19].
Further SNPs have been found and analyses of haplo-
types suggest a more complex genetic regulation of IL-6
[20]. Identification of functional SNP haplotypes and re-
examination of these disease cohorts will be necessary.
Interleukin 10
The hypothesis that the expression of the anti-inflamma-
tory cytokine IL-10 is genetically lower in the more severe
JIA subtype was tested by case–control and transmission
disequilibrium test association studies. The production of
IL-10 was lower in the parents of children with persistent
oligoarticular-onset JIA, and these parents have a signifi-
cantly increased frequency of nucleotide changes at posi-
tions –1082, –819 and –592 that combine to give the
‘ATA’ IL-10 haplotype [21]. The children with the more
severe disease (extended JIA) have a significantly
increased frequency of the IL-10 ATA haplotype. Trans-
mission disequilibrium test confirmed the disease associa-
tion of the IL-10 ATA allele with this group of children. In
contrast, Donn et al. [19] did not find evidence of IL-10 as
a susceptibility gene for JIA when the frequency of
nucleotide changes at positions –1082, –819 and –592
was compared in JIA patients and controls in a large asso-
ciation study.
Interferon regulatory factor 1
A positive association with a novel polymorphism in the 3′
untranslated region of the interferon regulatory factor
(IRF)-1 gene, which maps to a ‘cytokine gene cluster’ on
the long arm of chromosome 5 (5q31), has been
described [19]. In a study of synovial tissue cytokine
mRNA expression, Scola et al. [22] found a predominantly
Th1 bias, with a significant role of IL-12 in contributing to
this effect. A particular allele of a variable number tandem
repeat within the IL-1 receptor antagonist gene (IL1RN*2)
has been studied in JIA patients and a positive association
observed. Vencovsky et al. [23] also suggested that the
IL1RN*2 allele could be a useful prognostic marker for
extended oligoarticular JIA. The numbers included in this
study were relatively small, however, suggesting that
further investigation should now be considered, using a
large panel of well characterised oligoarticular-JIA patients
with a defined study outcome.
Macrophage migration inhibitory factor
Meazza  et al. [24] have described raised levels of
macrophage migration inhibitory factor (MIF) protein in
Italian JIA patients. A novel polymorphism in the 5′ flanking
region of the MIF gene was reported to be associated, ini-
tially with UK systemic-onset JIA [25], and subsequently
with susceptibility to all types of JIA, irrelevant of subgroup
[26]. MIF is a unique molecule that has pro-inflammatory,
hormonal and enzymatic properties (reviewed in [27]). The
unique induction of MIF that takes place at low glucocorti-
coid concentrations, together with its ability to counter-reg-
ulate glucocorticoid immunosuppressive actions, implies a
potentially important role of MIF in the control of the
immune response. The functional significance of the –173
polymorphism of MIF has now also been determined and
supports the genetic association observed for JIA [28].
T cell studies and JIA
JIA is thought to be an autoimmune condition (or possibly
group of conditions) in which the immune response to
self-antigen, present within the inflamed joint, plays a
central role. But what is the nature of this antigen? Since
several well-described HLA associations are known for
juvenile arthritis it has been tempting to try to extrapolate
from these to suggest the initiating pathogenic
organism(s). Albani [29] has shown that the Escherichia
coli heat shock protein DNAJ specifically binds within the
groove of HLA class II alleles known to be associated with
pauciarticular juvenile chronic arthritis. Subsequently,
work with synthetic peptides from E. coli DNAJ suggested
that T-lymphocyte reactivity may be critical to T-cell regula-
tory mechanisms that affect the course of joint inflamma-
tion in oligoarticular-JIA patients [30]. In an allied
approach Kamphuis et al. [31] generated putative self-epi-
topes in silico from the rat model of adjuvant arthritis. A
selection of human analogues of the recognized peptides
in adjuvant arthritis were made and tested for T-cell recog-
nition in JIA patients, by measuring proliferative activity of
peripheral blood mononuclear cells. Four of the selected
peptides were recognised by 20–40% of JIA patients.
Amongst these were peptides from matrix metallopro-
teinases, and also from proteoglycan/aggregan molecules.
Such an approach has implications for the better identifi-
cation of autoreactive T cells involved in JIA and the initiat-
ing micro-organisms that may be involved.
Wedderburn  et al. [32], using high-resolution heterodu-
plex TCR analysis, have recently shown multiple clonal T-
cell expansions that are present and persistent within the
joints of patients with enthesitis-related (HLA-B27-posi-
tive) arthritis and oligoarthritis. The dominant T-cell subset
containing these expansions showed disease-specific
divergence, however, such that for the class I associated305
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subgroup the dominant clones were in the CD8+ synovial
T cell population whereas for class II associated
oligoarthritis the dominant clones were within the CD4+
synovial T cell population. This is supportive evidence that
the recognition of MHC/peptide complexes by T cells
plays a critical role in the pathogenesis of JIA [32].
It is also noteworthy that analysis of the third hypervariable
region of HLA-associated alleles (HLA-DRB1*08,*11,*13)
reveals that they share a common motif (FLED) in their
protein sequence. Studies aimed at identifying relevant
homologies to potential organisms that could be cross-
reactive to FLED could offer a useful approach to further
understanding JIA pathology.
Conclusion: What should be the future
direction of JIA genetics?
Unified nomenclature, universally accepted and applied,
would be beneficial. In addition, we need to develop ways to
avoid the ‘pre-emptive strike’ of selecting candidate genes.
The idea of identifying ‘novel’ transcripts of relevance to
disease is obviously attractive. Expression (microarray-
based) technology could be useful if the correct sample
material were available, such as paired blood and synovial
fluids. This would allow us to look at alterations in mRNA
levels as an indication of gene activation or regulation. This
type of work, however, requires serial samples (say, before
and after treatment) that may not always be ethically accept-
able when studying disease in children.
The majority of the genetic research conducted for JIA so
far has been retrospective in nature. This may identify
genes involved in disease susceptibility. Perhaps the more
useful and clinically relevant genetic approach is to define
genetic predictors of outcome or disease severity. This
can be attempted by prospectively following a cohort of
clinically well-defined patients. Again the issue of multiple
samples becomes important and possibly limiting. Identify-
ing, at initial presentation, patients who are most likely to
have the more aggressive course of disease would have
substantial implications for treatment interventions.
For our understanding of JIA genetics to progress, interna-
tional collaborations that maximise the resource potential
would appear to be the way forward. This should allow
larger-scale association and linkage studies to be carried
out. Coupled with the rapid advances in genomic and pro-
teomic technologies, these studies should pave the way
forward to a better understanding of this complex genetic
disease.
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